Curated News
By: NewsRamp Editorial Staff
June 25, 2026

Quantum BioPharma Targets MS with Novel Myelin-Repair Drug

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS targets myelin repair, offering a competitive edge over current MS therapies that only slow progression.
  • Lucid-MS is a patented drug candidate designed to directly repair myelin damage in MS, advancing toward Phase 2 trials.
  • Lucid-MS aims to restore what MS takes away, improving quality of life for millions with a progressive neurological disease.
  • Unlike existing treatments, Lucid-MS seeks to reverse myelin degradation, potentially changing how multiple sclerosis is treated.

Impact - Why it Matters

This news matters because multiple sclerosis affects nearly 3 million people globally, and current treatments only slow progression. Quantum BioPharma’s Lucid-MS represents a potential paradigm shift—aiming to repair myelin damage rather than just manage symptoms. If successful in Phase 2 trials, it could offer patients a therapy that restores lost function, fundamentally changing the MS treatment landscape. For investors, it highlights a promising biotech with a novel approach and a diversified pipeline.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making headlines with its innovative approach to treating multiple sclerosis (MS), a debilitating neurological disease affecting over 2.9 million people worldwide. The company is featured in a BioMedWire editorial titled “The Quest to Repair What Multiple Sclerosis Takes Away,” which underscores the urgent need for new therapies. Current MS treatments can only slow progression, not stop it, leaving patients with limited options. Quantum BioPharma is developing Lucid-MS, a patented, first-in-class drug candidate that directly targets the myelin sheath—the protective layer around nerves that is damaged in MS. The therapy is poised to enter Phase 2 clinical trials, offering hope for a novel approach that could potentially reverse myelin degradation.

The news release, disseminated via Quantum BioPharma Ltd., details the company’s broader portfolio. Through its subsidiary Lucid Psycheceuticals Inc., Quantum focuses on neurodegenerative and metabolic disorders, as well as alcohol misuse. Lucid-MS has shown preclinical success in preventing and reversing myelin degradation. Additionally, Quantum invented UNBUZZD(TM), a product for alcohol misuse, and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% stake and royalty payments of 7% of sales until $250 million, then 3% in perpetuity. The company retains full rights for pharmaceutical and medical uses of similar formulations.

BioMedWire, part of the Dynamic Brand Portfolio @ IBN, provides a platform for breaking biotech news. The editorial highlights the critical need for therapies that repair rather than just slow MS. For investors, the latest updates on QNTM are available in the company’s newsroom. With a seasoned team and broad reach, BioMedWire brings such developments to a wide audience, emphasizing the potential impact of Quantum’s work on the lives of millions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Targets MS with Novel Myelin-Repair Drug

blockchain registration record for this content.